13.09.2012

Publication list ANDRI RAUCH, MD A) Original articles Bold: First or corresponding author Nr. 1

2

3

4

5

6

7

8

9

10

11

A Rauch, M Rickenbach, R Weber, B Hirschel, P Tarr, H Bucher, P Vernazza, E Bernasconi, AS Zinkernagel, J Evison, H Furrer. Unsafe sex and increasing incidence of Hepatitis C Virus infection among HIV infected men who have sex with men: The Swiss HIV Cohort Study. Clinical Infectious Diseases 2005;41:395- 402. A Rauch, M Egger, J Reichen, HJ Furrer. Chronic hepatitis C in HIV-infected patients: Low eligibility and applicability of therapy with pegylated interferon alfa plus ribavirin. Journal of AIDS 2005;38:238-40. (original research letter) A Rauch, D Nolan, A Martin, E McKinnon, C Almeida, S Mallal. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort. Clinical Infectious Diseases 2006;43:99-102. S Gaudieri*, A Rauch*, L Park, E Freitas, S Herrmann, G Jeffrey, W Cheng, K Pfafferott, Vanessa Naidoo, Russell Chapman, Manuel Battegay, Rainer Weber, Amalio Telenti, Hansjakob Furrer, Ian James, Michaela Lucas, Simon A Mallal. Evidence of viral adaptation to HLA Class I-restricted immune pressure in chronic Hepatitis C virus infection. Journal of Virology 2006; 80:11094-104. *shared first authors M Lucas, A Ulsenheimer, K Pfafferot, MH Heeg, S Gaudieri, N Grüner, A Rauch, J Tilman Gerlach, MC Jung, R Zachoval, G Pape, W Schraut, T Santantonio, H Nitschko, M Obermeier, R Phillips, T Scriba, N Semmo, C Day, J Weber, S Fidler, R Thimme, A Heberstroh, TF Baumert, P Klenerman, H Diepolder. Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS ONE 2007; 7:e649. A Rauch, Silvana Gaudieri, John Evison, David Nolan, Matthias Cavassini, Rainer Weber, Ian James, Hansjakob Furrer. Low current and nadir CD4 Tcell counts are associated with higher Hepatitis C viral loads in the Swiss HIV Cohort Study. Antiviral Therapy, 2008;13:455-60. *corresponding author A Rauch*, D Nolan, H Furrer, E McKinnon, M John, S Mallal, S Gaudieri, H Günthard, P Schmid, M Battegay, B Hirschel, A Telenti, I James. HLA-Bw4 Homozygosity Is Associated with an Impaired CD4 T Cell Recovery after Initiation of Antiretroviral Therapy. Clinical Infectious Diseases, 2008; 46:1921-5. *corresponding author S Colombo*, A Rauch*, M Rotger, J Fellay, R Martinez, C Fux, C Thurnheer, H Günthard, D Goldstein, H Furrer, A Telenti. The HCP5 Single-Nucleotide Polymorphism: A Simple Screening Tool for Prediction of Hypersensitivity Reaction to Abacavir. Journal of Infectious Diseseas, 2008;198:864-7 . *shared first authors A Rauch*, D Nolan, C Turnheer, C Fux, M Cavassini, J Chave, M Opravil, E Phillips, S Mallal, H Furrer. Refining Abacavir Hypersensitivity Diagnoses using Structured Clinical Asessment and Genetic Testing in the Swiss HIV Cohort Study. Antiviral Therapy, 2008;13:1019-28. *corresponding author G Clifford, M Rickenbach, J Polesel, L Dal Maso, I Steffen, B Ledergerber, A Rauch, N Probst-Hensch, C Bouchardy, F Levi, S Franceschi. Influence of HIV related immunodeficiency on the risk of hepatocellular carcinoma. AIDS, 2008;22:2135-41. C Fux, A Rauch, M Simcock, H Bucher, B Hirschel, M Opravil, P Vernazza, M Cavassini, E Bernasconi, L Elzi, H Furrer. Tenofovir use is associated with an

IF 2011

Ranking

9.154

0,986

4,425

0,857

9.154

0,986

5.44

0,844

4.092

0.867

3.161

0,741

9.154

0,986

6.41

0,971

3.161

0,741

6,245

0.957

3.161

0,741

12

13

14

15

16

17

18

19

20

21

22

23

24

increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antiviral Therapy, 2008;13:1077-82. S Gaudieri, A Rauch, K Pfafferott, E Barnes, W Cheng, G McCaughan, N Shackel, G Jeffrey, L Mollison, R Baker, H Furrer, H Günthard, E. Freitas, I. Humphreys, P Klenerman, S Mallal, I James, S Roberts, D Nolan, M Lucas. Hepatitis C Virus Drug Resistance and Immune-Driven Adaptations: Relevance to New Antiviral Therapy. Hepatology, 2009 Apr;49(4):1069-82. C Combescure, N Vallier, B Ledergerber, M Cavassini, H Furrer, A Rauch, M Battegay, E Bernasconi, P Vernazza, B Hirschel. How Reliable Is An Undetectable Viral Load? HIV-Medicine, 2009 Sep;10(8):470-6. A Kesselring, F Wit, C Sabin, J Lundgren, M Gill, J Gatell, A. Rauch, J. Montaner, F de Wolf, P. Reiss, A. Mocroft. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS, 2009 24;23:1689-99. M Tschochner, A Chopra, TM Maiden, IF Ahmad, I James, HJ Furrer, HF Günthard, S Mallal, A Rauch, M John. Effects of HIV-1 immune selection on susceptibility to integrase inhibitor resistance, Antiviral Therapy, 2009;14(7):953-64. T Ferry, B Hirschel, T Dang, P Meylan, C Delhumeau, A Rauch, R Weber, L Elzi, E Bernasconi, P Schmid, A Calmy, the Swiss HIV Cohort Study. Infrequent Replication of Parvovirus B19 and Erythrovirus Genotypes 2 and 3 among HIV-Infected Patients with Chronic Anemia. Clinical Infect Diseases, 2010 Jan 1;50(1):115-8. M May, R Wood, L Myer, P Taffé, A Rauch, M Battegay, M. Egger. CD4+ T Cell Count Decreases by Ethnicity among Untreated Patients with HIV Infection in South Africa and Switzerland. Journal of Infectious Diseases. 2009 1;200(11):1729-35. A Rauch, I James, K Pfafferott, D Nolan, P Klenerman, W Cheng, L Mollison, G McCaughan, N Shackel, GP Jeffrey, R Baker, E Freitas, I Humphreys, H Furrer, H Günthard, B Hirschel, S Mallal, M. John, M. Lucas, E. Barnes, S. Gaudieri. Divergent Adaptation of Hepatitis C Virus Genotypes 1 and 3 to Human Leukocyte Antigen–Restricted Immune Pressure. Hepatology, 2009;50(4):1017-29. A Rauch*, Z Kutalik, P Descombes, T Cai, J Di Iulio J, T Mueller, M Bochud, M Battegay, E Bernasconi, E Borovicka, S Colombo, A Cerny JF Dufour, H Furrer, H Günthard, M Heim, B Hirschel, R Malinverni, D Moradpour, B Müllhaupt, A Witteck, J Beckmann, T Berg, S Bergmann, F Negro, A Telenti, PY Bochud.Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010 Apr;138(4):1338-45. *corresponding author Kovari H, Ledergerber B, Battegay M, Rauch A, Hirschel B, Foguena AK, Vernazza P, Bernasconi E, Mueller NJ, Weber R. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infectionClin Infect Dis. 2010 Feb 15;50(4):502-11. Casado C, Colombo S, Rauch A, Martínez R, Günthard HF, Garcia S, Rodríguez C, Del Romero J, Telenti A, López-Galíndez C. Host and viral genetic correlates of clinical definitions of HIV-1 disease progression. PLoS One. 2010 Jun 11;5(6):e11079. S Gianella, V von Wyl, M Fischer, B Niederöst, M Battegay, E Bernasconi, M Cavassini, A Rauch, B Hirschel, P Vernazza, R. Weber, B Joos, H Günthard. Effect of Early Antiretroviral Therapy during primary HIV-1 infection on cellassociated HIV-1 DNA and Plasma HIV-1 RNA. Antiviral Therapy 2011;535-45. R Kouyos, V von Wyl, S Yerly, J Böni, P Rieder, B Joos, P Taffé, C Shah, P Bürgisser, T Klimkait, R Weber, B Hirschel, M Cavassini, A Rauch, M Battegay, P Vernazza, E Bernasconi, M Rickenbach, B Ledergerber, S Bonhoeffer, H Günthard. Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. Clinical Infectious Diseases. 2011 15;532-9. S Alizon, V von Wyl, T Stadler, R Kouyos, S Yerly, B Hirschel, J Böni, C Shah, T Klimkait, H Furrer, A Rauch, P Vernazza, E Bernasconi, M Battegay M, P

11,665

0,986

2,878

0,684

6.245

0,957

3.161

0,741

9.154

0,986

6.41

0,971

11,665

0,986

11,675

1

9.154

0,986

4.092

0.867

3.161

0,741

9.154

0,986

9.127

0.97

25

26

27

28

29

30

31

32

33

34

35

36

37

Bürgisser, A Telenti, H Günthard, S Bonhoeffer S. Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathogens. 2010;6(9):e1001123. J Rohrbach, N Robinson, G Harcourt, E Hammond, S Gaudieri, M Gorgievski, A Telenti, O Keiser, H Günthard, B Hirschel, M Hoffmann E Bernasconi, M Battegay, H Furrer, P Klenerman, A Rauch*. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut 2010;59:1252-1258. *Corresponding author A Nguyen, A Calmy, C Delhumeau. IK Mercier, M Cavassini, A Fayet-Mello, L Elzi, D Genné D, A Rauch, E Bernasconi, B Hirschel. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS 2011, 25:57–63. S Merani, D Petrovic, I James, A Chopra, D Cooper, E Freitas, A Rauch, J di Iulio, D Cooper, M John, M Lucas, K Fitzmaurice, S McKiernan, S Norris, D Kelleher, P Klenerman, S Gaudieri. Effect of immune pressure on Hepatitis C virus evolution: insights from a single source outbreak. Hepatology;53:396405. K Pfafferott, S Gaudieri, A Ulsenheimer, I James, M Heeg, D Nolan, M John, A Rauch, S Mallal, A Lucas, P Klenerman, HM Diepolder, M Lucas. Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity. Plos One 2011;8:e16797. Keiser O, Spycher B, Rauch A, Calmy A, Cavassini M, Glass TR, Nicca D, Ledergerber B, Egger M. Outcomes of Antiretroviral Therapy in the Swiss HIV Cohort Study: Latent Class Analysis. AIDS Behav. 2012 Feb;16(2):245-55. Nguyen A, Calmy A, Delhumeau C, Mercier I, Cavassini M, Mello AF, Elzi L, Rauch A, Bernasconi E, Schmid P, Hirschel B. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS 2011 Jul 31;25(12):1481-7. J di Iulio J, A Ciuffi, K Fitzmaurice, D Kelleher, M Rotger, J Fellay, R Martinez, S Pulit, H Furrer, HF Günthard, M Battegay, E Bernasconi, P Schmid, B Hirschel, E Barnes, P Klenerman, A Telenti, A Rauch*. Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology, 2011; 53 (5):1446-54.*corresponding author *M Rotger, *J Dalmau, *A Rauch, *P McLaren, *S Bosinger, R Martinez, NG Sandler, A Roque, J Liebner, M Battegay, E Bernasconi, P Descombes I Erkizia, J Fellay, B Hirschel, M Miró, E Palou, M Hoffmann, M Massanella, J Blanco, M Woods, HF Günthard, P de Bakker, DC Douek, G Silvestri, J Martinez-Picado, A Telenti. Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest. 2011 May 9. *shared first authors K. Mühlethaler, K Bögli, S Wasmer, C von Garnier, P Dumont, A Rauch, K Mühlemann, C Garzoni. Quantitative PCR to diagnose pneumocystis pneumonia in immunocompromised non-HIV patients. Eur Respir J. 2012; 39:971-8. N Boillat, A Probst, V Da Costa, S Giulieri, E Bernasconi, A Calmy, L Elzi, A Rauch, R Weber, B Bertisch, M Cavassini, PY Bochud. Impact of a Nurse Vaccination Program on Hepatitis B Immunity in a Swiss HIV Clinic. J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):472-474. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Scherrer AU, Ledergerber B, von Wyl V, Böni J, Yerly S, Klimkait T, Bürgisser P, Rauch A, Hirschel B, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Held L, Günthard HF; Swiss HIV Cohort Study. Clin Infect Dis. 2011 Dec;53(11):1143-52. Epub 2011 Oct 13. von Wyl V, Gianella S, Fischer M, Niederoest B, Kuster H, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B, Günthard HF; the Swiss HIV Cohort Study (SHCS).Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. PLoS One. 2011;6(11):e27463. Epub 2011 Nov 15 M Stern, K Czaja, A Rauch, M Rickenbach, H F Günthard, M Battegay, J Fellay, B Hirschel, C Hess and the Swiss HIV Cohort Study Group. HLA-Bw4 identifies a population of HIV-infected patients with an increased capacity to

10.111

0.973

6.245

0,957

11,665

0,986

4.092

0.867

3.949

0.973

6.245

0,957

11,665

0,986

13.079

0.972

5.895

0.958

4,425

0,857

9.154

0,986

4.092

0.867

3.00

0.614

38

39

40

41

42

43

44

control viral replication after structured treatment interruption. HIV Medicine. 2012; Epub ahead of print. S. Gaudieri, M. Lucas, A. Lucas, E. McKinnon, H. Albloushi, A. Rauch, J. di Iulio, D. Di Martino, S. Prescott, MK. Tulic. Genetic variations in IL28B and allergic diseases in children. PLOS One, 2012;7(1):e30607. Epub 2012 Jan 25 C Smit, JA Sterne, A. d’Aminio Monforte, M. Puoti, F. de Wolf, L. Peters, B. Ledergerber, S. de Wit, H. Sambatakou, A. Rauch, F. Dabis on behalft of the COHERE collaboration. Effect of Hepatitis C treatment on CD4 cell counts and the risk of death in HIV-hepatitis C co-infected patients. Antiviral Therapy, 2012; Epub ahead of print. SK Pillai, MA bdel-Mohsen, J Guatelli, M Skasko, A Monto, K Fujimoto, S Yukl, W Greene, A Rauch, J Fellay, M Battegay, B Hirschel, A Witteck, E Bernasconi, B Ledergerber, H Günthard, J Wong, and the Swiss HIV Cohort Study. Role of retroviral restriction factors in the interferon-γ-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A. 2012 21;109(8):303540. Scherrer AU, Ledergerber B, von Wyl V, Böni J, Yerly S, Klimkait T, Bürgisser P, Rauch A, Hirschel B, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Held L, Günthard HF; Swiss HIV Cohort Study. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B Clin Infect Dis. 2011 Dec;53(11):1143-52. R Simmons, C Sharp, C McClure, J Rohrbach, H Kovari, E Frangou, P Simmonds, W Irving, A Rauch, P Bowness, P Klenerman, and the Swiss HIV Cohort Study. Parvovirus 4 Infection and Clinical Outcome in High-Risk Populations. J Infect Dis. 2012 Jun 15;205(12):1816-20. Gasser O, Brander C, Wolbers M, Brown N, Rauch A, Günthard H, Battegay M, Hess C; the Swiss HIV Cohort Study. Expansion of interferon-γ-secreting HIV-specific T cells during successful antiretroviral therapy. HIV Med. 2012 Aug 30. Epub ahead of print. Wandeler G, Gsponer T, Bregenzer A, Günthard HF, Clerc O, Calmy A, Stöckle M, Bernasconi E, Furrer H, Rauch A*; the Swiss HIV Cohort Study. Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic. Clin Infect Dias. 2012. Aug 14. Epub ahead of print. .*corresponding author

4.092

0.867

3.161

0,741

9.681

9.154

0,986

6.41

0.971

3.00

0.614

9.154

0,986

B) Case Reports 1 2 3 4

A Rauch, M Egger, M Täuber. Unusual cause of diarrhea. Swiss Medical Forum. 2004;22:220-3. Ch Hurni, A Rauch, N Trost, M Perrig, U Bürgi, AW Schoenenberger. Pulmonary nodules and prednison therapy. Praxis 2008, 97:849-852. A Rauch, S Droz, S Zimmerli, S Leib. Dysphagia in Elderly Women: Consider Tetanus. Infection 2006; 34:35-8. Wandeler G, Furrer H, Rauch A. Sustained virological response to a raltegravircontaining salvage therapy in an HIV-2-infected patient. AIDS. 2011 Nov 28;25(18):2306-8.

no IF no IF 2.659

0.529

6.245

0,957

4.536

0,884

C) Reviews 1 2 3 4

A Martin, D Nolan, CA Almeida, A Rauch, S Mallal. Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again. Pharmacogenomics 2006 7:15-23. A. Lucas, S. Gaudieri, A. Rauch, D. Nolan. Cellular tropism of HIV-1 mediated and constrained by coreceptro dependencies. 2005. J Viral Entry, 1, 17-27. A Rauch, R Laird, E McKinnon, A Telenti, H Furrer, R Weber, D Smillie, S Gaudieri; and the Swiss HIV Cohort Study. Influence of inhibitory KIRs and their HLA-C ligands on resolving HCV infection. Tissue Antigens 2006;69 Suppl 1:237-40. A Rauch*, S Gaudieri, C Thio, PY Bochud. Host Genetic Determinants of Spontaneous Hepatitis C Clearance. Pharmacogenomics. 2009 Nov;10(11):181937. *corresponding author

No IF 2.588

0,705

4.536

0,884

5 6 7

A Rauch*, J Rohrbach, PY Bochud. The recent breakthroughs in the understanding of host genomics in hepatitis C. Eur J Clin Invest. 2010 Oct;40(10):950-9. *corresponding author A Rauch*, J Fellay. Personalized Hepatitis C Therapy: Opportunities and Pitfalls. Expert Reviews of Molecular Diagnostics, 2011;127-9. *corresponding author The European AIDS Treatment Network (NEAT) Acute Hepatitis C (AHC) consensus panel: Acute hepatitis C in HIV-infected individuals – recommendations from the NEAT consensus conference. AIDS 2011;25:399-409.

3.018

0.869

3,693

0.817

6.245

0,957